PMID- 17439415
OWN - NLM
STAT- MEDLINE
DCOM- 20070815
LR  - 20181201
IS  - 0305-1870 (Print)
IS  - 0305-1870 (Linking)
VI  - 34
IP  - 5-6
DP  - 2007 May-Jun
TI  - Rosiglitazone, an agonist of peroxisome proliferator-activated receptor-gamma, 
      prevents contralateral testicular ischaemia-reperfusion injury in prepubertal 
      rats.
PG  - 457-61
AB  - 1. Rosiglitazone plays a positive role in the reparation of ischaemia-reperfusion 
      (I/R) injury in different tissues. Thus, we examined its biochemical and 
      histological effects on the contralateral testes to determine whether exogenous 
      rosiglitazone affords any protection against testicular damage. 2. Forty-eight 
      prepubertal male Wistar-Albino rats were divided into six groups. Testicular 
      torsion was created by rotating the right testis 720 degrees in a clockwise 
      direction for 5 h in all groups except group I, which was the sham-control group. 
      In group II, bilateral orchiectomy was performed following the torsion period. 
      After detorsion both testes were removed in the fifth hour in group III and on 
      the seventh day in group IV. In group V, one-shot rosiglitazone (4 mg/kg) was 
      administered 40 min before detorsion and both testes were removed following the 
      torsion period. In group VI, rosiglitazone was administered (4 mg/kg) 40 min 
      before detorsion and for 7 days, and then both testes were harvested. The tissue 
      levels of malondialdehyde (MDA) were measured and mean testicular biopsy score 
      (MTBS) and mean seminiferous tubule diameter (MSTD) were examined. 
      Immunoexpression of endothelial nitric oxide synthase (eNOS) in testes tissues 
      was investigated by immunohistochemical studies. 3. In the contralateral testis, 
      the MTBS and MSTD values of group VI were significantly higher than those in 
      group IV. Immunohistochemically, mild eNOS immunostaining was present in the germ 
      cells of the contralateral testes in group IV after I/R. In group VI, intense 
      eNOS immunoreactivity was seen in the contralateral testes. 4. Rosiglitazone 
      reduces contralateral testicular damage formed after unilateral testicular 
      torsion and alleviates the oxidative events.
FAU - Inan, Mustafa
AU  - Inan M
AD  - Department of Pediatric Surgery, Trakya University Faculty of Medicine, Edirne, 
      Turkey. mustafainan@trakya.edu.tr
FAU - Basaran, Umit
AU  - Basaran U
FAU - Dokmeci, Dikmen
AU  - Dokmeci D
FAU - Kanter, Mehmet
AU  - Kanter M
FAU - Yalcin, Omer
AU  - Yalcin O
FAU - Aydogdu, Nurettin
AU  - Aydogdu N
FAU - Turan, Nesrin
AU  - Turan N
LA  - eng
PT  - Journal Article
PL  - Australia
TA  - Clin Exp Pharmacol Physiol
JT  - Clinical and experimental pharmacology & physiology
JID - 0425076
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (PPAR gamma)
RN  - 0 (Thiazolidinediones)
RN  - 05V02F2KDG (Rosiglitazone)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
SB  - IM
MH  - Animals
MH  - Dose-Response Relationship, Drug
MH  - Germ Cells/cytology/drug effects/metabolism
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Immunohistochemistry
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Nitric Oxide Synthase Type III/metabolism
MH  - Orchiectomy
MH  - PPAR gamma/*agonists
MH  - Rats
MH  - Rats, Wistar
MH  - Reperfusion Injury/metabolism/physiopathology/*prevention & control
MH  - Rosiglitazone
MH  - Seminiferous Tubules/cytology
MH  - Spermatic Cord Torsion/physiopathology
MH  - Spermatogenesis/drug effects
MH  - Testis/blood supply/*drug effects/pathology
MH  - Thiazolidinediones/*pharmacology/therapeutic use
MH  - Time Factors
EDAT- 2007/04/19 09:00
MHDA- 2007/08/19 09:00
CRDT- 2007/04/19 09:00
PHST- 2007/04/19 09:00 [pubmed]
PHST- 2007/08/19 09:00 [medline]
PHST- 2007/04/19 09:00 [entrez]
AID - CEP4594 [pii]
AID - 10.1111/j.1440-1681.2007.04594.x [doi]
PST - ppublish
SO  - Clin Exp Pharmacol Physiol. 2007 May-Jun;34(5-6):457-61. doi: 
      10.1111/j.1440-1681.2007.04594.x.